Ozempic (Semaglutide) Patent Expiration, LOE Window & CMS Spending

Ozempic (Semaglutide) by Novo Nordisk: FDA Orange Book core substance LOE 2031-12-05 (last listed 2041-02-17), 0 AB generics, $16.38B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovo Nordisk
FDA Application & PathwayN209637 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-12-05
Last Listed Patent or Exclusivity Date2041-02-17
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$16.38B
2024 Medicare Part D Spend$12.97B
2024 Medicaid Spend$3.41B
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.